Agios Pharmaceuticals, Inc. (FRA:8AP)

Agios Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	54.03	36.5	26.82	14.24	-
Revenue Growth (YoY)	48.03%	36.07%	88.36%	-	-
Cost of Revenue	345.88	305.45	298.41	281.61	256.97
Gross Profit	-291.85	-268.95	-271.58	-267.37	-256.97
Selling, General & Admin	180.28	156.78	119.9	121.67	121.45
Operating Expenses	180.28	156.78	119.9	121.67	121.45
Operating Income	-472.13	-425.74	-391.49	-389.05	-378.42
Interest & Investment Income	56.38	48.08	33.34	12.79	0.84
Other Non Operating Income (Expenses)	1.96	6.49	6.06	16.6	21.07
EBT Excluding Unusual Items	-413.8	-371.17	-352.09	-359.65	-356.51
Gain (Loss) on Sale of Assets	-	200	-	-	-
Other Unusual Items	-	889.14	-	127.85	-
Pretax Income	-413.8	717.97	-352.09	-231.8	-356.51
Income Tax Expense	-1.02	44.24	-	-	-
Earnings From Continuing Operations	-412.78	673.73	-352.09	-231.8	-356.51
Earnings From Discontinued Operations	-	-	-	-	1,961
Net Income	-412.78	673.73	-352.09	-231.8	1,605
Net Income to Common	-412.78	673.73	-352.09	-231.8	1,605
Shares Outstanding (Basic)	58	57	56	55	60
Shares Outstanding (Diluted)	58	58	56	55	60
Shares Change (YoY)	0.14%	4.02%	1.57%	-9.36%	-12.39%
EPS (Basic)	-7.12	11.86	-6.33	-4.23	26.55
EPS (Diluted)	-7.12	11.64	-6.33	-4.23	26.55
Free Cash Flow	-377.29	-391.53	-297.06	-314.36	-413.06
Free Cash Flow Per Share	-6.51	-6.76	-5.34	-5.74	-6.83
Operating Margin	-873.87%	-1166.47%	-1459.52%	-2732.07%	-
Profit Margin	-764.01%	1845.92%	-1312.63%	-1627.82%	-
Free Cash Flow Margin	-698.33%	-1072.73%	-1107.49%	-2207.58%	-
EBITDA	-466.96	-420.08	-384.86	-380.48	-369.18
D&A For EBITDA	5.18	5.65	6.62	8.56	9.24
EBIT	-472.13	-425.74	-391.49	-389.05	-378.42
Effective Tax Rate	-	6.16%	-	-	-
Revenue as Reported	54.03	36.5	26.82	14.24	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.